Pay in 4 interest-free payments of $22.50 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Molecular Weight: 1347
20)21)22-11-14-5-4-6-15(10-14)25-3/h4-11H
which are responsible for Src and Ras/MAPK signaling respectively
A Phase II study of intravenous exatecan administered daily for 5 days
CC-115 shows good in vivo PK profiles across multiple species with 53%
PF-06463922 5109 HCl Molecular Weight: 1347Lorlatinib, also known as PF 06463922, is an orally available, ATP competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, ALK ROS1 inhibitor PF 06463922 binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK and ROS1 mediated signaling and eventually inhibits tumor cell growth in ALK and